Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS) has announced a major milestone with over one million implantations of its iStent technology worldwide. This achievement underscores Glaukos' pioneering role in Micro-Invasive Glaucoma Surgery (MIGS), reflecting more than 20 years of innovation and investment in glaucoma treatment options.

Industry experts emphasize that iStent has significantly improved patient outcomes and allowed for earlier interventions in glaucoma treatment. Glaukos continues to invest over 30% of its revenue into research and development to enhance its product offerings.

On August 24, iVeena Delivery Systems entered a strategic licensing agreement with Glaukos Corporation (GKOS) for IVMED-80, an eye drop designated for keratoconus. Glaukos paid $10 million upfront and will cover all development costs. The deal includes potential milestone payments and royalties for iVeena. iVeena is also working on IVMED-85, aimed at pediatric myopia, with plans for a clinical trial in early 2023.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, has announced its management will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 3:45 p.m. ET in Boston, MA. This event will highlight Glaukos' focus on novel therapies for treating glaucoma, corneal disorders, and retinal diseases. A live webcast will be available in the Investors section of the Glaukos website.

iVeena Delivery Systems has entered a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) for exclusive global rights to IVMED-80, a treatment for keratoconus, a rare corneal disorder. IVMED-80 is a proprietary topical eye drop that has shown promising results in a phase 1/2a clinical study, achieving a significant reduction in corneal curvature. Glaukos paid $10 million upfront for the license and will cover all development costs, with further milestone payments and royalties possible. This partnership aims to enhance treatment options for keratoconus patients.

Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iStent infinite Trabecular Micro-Bypass System, the first micro-invasive implantable device approved for standalone glaucoma treatment. This innovative device features a three-stent system designed to lower intraocular pressure (IOP) by restoring natural fluid outflow. CEO Thomas Burns highlighted the device's potential, backed by compelling clinical data. Initial commercial launch activities for iStent infinite are planned for later this year.

Glaukos Corporation (NYSE: GKOS) reported Q2 2022 net sales of $72.7 million, a decrease from $78.1 million in Q2 2021. Key segments included $56.1 million from glaucoma and $16.6 million from corneal health. Gross margin was approximately 75%, down from 77% year-over-year. Notably, R&D expenses surged 31% to $31.7 million. Glaukos raised its full-year revenue guidance to $275 million to $280 million, up from $270 million to $275 million. The company ended the quarter with approximately $400 million in cash and equivalents.

Glaukos Corporation (NYSE: GKOS) is scheduled to release its Q2 2022 financial results after the market closes on August 3, 2022. The management will hold a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast on the company's website. Glaukos focuses on innovative therapies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012.

Glaukos Corporation (NYSE: GKOS) announced its participation in the William Blair 42nd Annual Growth Stock Conference scheduled for June 8, 2022, at 8:40 a.m. CT in Chicago, IL. The event will feature a live and archived webcast available on the company's investor relations website. Glaukos focuses on innovative ophthalmic medical technologies targeting glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its first device launched in 2012. The company continues to advance treatment options in these areas through ongoing innovations.

Glaukos Corporation (NYSE: GKOS) announced its virtual participation in the Piper Sandler Ophthalmology Symposium on May 23, 2022, at 2:00 p.m. ET. The company is focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional treatments, launching its first MIGS device in 2012. The event will feature a live and archived webcast accessible through the Glaukos Investors section.